After Leerink Partners and Wedbush gave ObsEva SA (NASDAQ: OBSV) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA today and set a price target of $44. The company’s shares closed on Friday at $16.30.
Selvaraju observed:
“Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.68B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban. The current total valuation of $1.85B translates to $44.00 per share, assuming roughly 42M fully-diluted shares outstanding as of mid-2019. The fully-diluted shares projected in 12 months include the issuance of 4.75M shares in the most recent follow-on financing, as well as the exercise of approximately 800,000 options currently outstanding.”
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -7.6% and a 28.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Synergy Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ObsEva SA with a $33.75 average price target, representing a 107.1% upside. In a report issued on October 3, Leerink Partners also maintained a Buy rating on the stock with a $27 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.35 and a one-year low of $8.79. Currently, ObsEva SA has an average volume of 100K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
